Data are n (%).	PBO + FBX	LESU200 + FBX	LESU400 + FBX
	N=109	N=106	N=109
Patients experiencing any TEAE	79 (72.5%)	87 (82.1%)	90 (82.6%)
Patients with serious TEAEs	10 (9.2%)	6 (5.7%)	9 (8.3%)
Patients with any renal-related AEs	6 (5.5%)	9 (8.5%)	11 (10.1%)
Patients with serious renal-related AEs	1 (0.9%)	0 (0%)	2 (1.8%)
Patients with kidney stones	4 (3.7%)	1 (0.9%)	2 (1.8%)
Patients with ≥2.0x increase in sCr	0 (0%)	3 (2.8%)	6 (5.5%)
Number (%) sCr elevations resolved at last study visit	–	2/3 (67%)	6/7 (86%)